- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07681258
A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region (ASC4Young)
ASC4Young: Real-World Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region
The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region. The data source for this study will consist of routinely collected clinical information documented within the electronic health records (EHR) of participating centers.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
CML patients who initiate asciminib between 01 May 2023 and 31 May 2026 in participating centers across the Gulf region.
Description
Inclusion Criteria
- Confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)
- Adult patients aged ≥ 18 years at the index date (or adult as defined by applicable national regulations)
- Documented exposure to asciminib during the identification period (May 2023 to May 2026)
- Provision of signed informed consent for secondary use of data, or an ethics committee-approved waiver of consent, where applicable (including for deceased patients or where data were previously collected within the EHR system)
Exclusion Criteria
- Patients who do not meet the eligibility criteria specified above
- Patients with insufficient medical record documentation to determine asciminib exposure or key study outcomes
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
Young Adults Cohort
CML patients aged ≤ 40 years at the first documented asciminib administration. |
|
Older Adults Cohort
CML patients aged > 40 years at the first documented asciminib administration. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Major Molecular Response (MMR) Rate in Young Adults
Time Frame: Approximately 12 Months
|
MMR is defined as a BCR::ABL1 level on the International Scale (BCR::ABL1 IS) ≤ 0.1%. |
Approximately 12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of Adverse Events (AEs)
Time Frame: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Treatment Interruptions Due to AEs
Time Frame: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions Due to AEs
Time Frame: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Time to Treatment Discontinuation due to Adverse Events (TTDAE)
Time Frame: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment
Time Frame: 3 months
|
3 months
|
|
|
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment
Time Frame: 6 months
|
6 months
|
|
|
Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
Time Frame: Up to 12 months prior to Baseline
|
Up to 12 months prior to Baseline
|
|
|
Duration of CML at Time of Asciminib Treatment Initiation
Time Frame: Baseline
|
Baseline
|
|
|
Asciminib Starting Dose
Time Frame: Baseline
|
Baseline
|
|
|
Number of Treatment Interruptions
Time Frame: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Duration of Treatment Interruptions
Time Frame: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching
Time Frame: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Reason for Treatment Switch
Time Frame: Approximately 3, 6, and 12 months
|
Approximately 3, 6, and 12 months
|
|
|
Number of Patients by Type and Severity of AEs
Time Frame: Approximately 3, 6, and 12 months
|
Number of patients by type and severity of AEs including serious AEs and grade ≥ 3 AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Approximately 3, 6, and 12 months
|
|
Incidence of AEs Leading to Dose Modifications
Time Frame: Approximately 3, 6, and 12 months
|
Dose modifications include treatment interruptions and dose reductions. |
Approximately 3, 6, and 12 months
|
|
MMR in Patients Aged > 40 years
Time Frame: Approximately 12 months
|
MMR is defined as BCR::ABL1 IS ≤ 0.1%. |
Approximately 12 months
|
|
Rate of Deep Molecular Response
Time Frame: Approximately 12 months
|
Deep molecular response includes:
|
Approximately 12 months
|
|
Number of Patients With Dose Modifications
Time Frame: Approximately 3, 6, and 12 months
|
Number of patients with dose modifications including up titration or dose reduction. |
Approximately 3, 6, and 12 months
|
|
Number of Patients by Clinicopathological Characteristics
Time Frame: Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
Clinicopathological characteristics include:
|
Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Chronic Disease
- Disease Attributes
- Neoplasms by Histologic Type
- Hematologic Diseases
- Leukemia, Myeloid
- Bone Marrow Diseases
- Leukemia
- Myeloproliferative Disorders
- Pathological Conditions, Signs and Symptoms
- Hemic and Lymphatic Diseases
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Other Study ID Numbers
- CABL001J1AE01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.